NEW YORK--(BUSINESS WIRE)--WallStAnalyst.com’s (SEBI Reg. # INH200000147) (www.wallstanalyst.com) ‘Weekly Screener’ brings investors the fundamental macroeconomic events and market news that shaped equities, commodities and currencies markets last week. It covers global equity indices’ performance, commodities’ movements and economic releases. Our analysts have also expanded our coverage to include the recent developments in the biotech sector with focus on these companies: Aeterna Zentaris Inc. (NASDAQ: AEZS), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Medivation Inc. (NASDAQ:MDVN) in our website’s Research Desk category. Visit us for your free biotech companies coverage at:
After The FOMC meeting on Thursday, September 17, 2015, confirmed that the Feds were not ready to increase interest rates in September; a string of disappointing economic data from the U.S. and China; Janet’s Yellen’s hawkish comments last Friday indicating that the Feds would now most probably be opting for a hike in rates by year’s end; and U.S. Democratic Presidential candidate for next year’s election campaign, Hillary Clinton, taking a firm stance against Bio Pharma’s culture of high prices for some key health products, our weekly analytical publication provides some insight to the current volatility impacting the equities and commodities markets. Read more from our complimentary Weekly Screener at:
Markets enter a busy week starting Monday, September 28, 2015, with jobs data, several Federal Reserve speakers scheduled to talk and the possibility of more brinksmanship in Washington over a potential government shutdown. As these events develop, WallStAnalyst.com’s analysts will be studying their impact on some selected equities and markets. Sign up now and read our free coverage as they are published premarket from Monday to Friday at:
The information within this report is provided to its recipients for informational purposes only and shall not be used or considered as an offer or solicitation to trade or subscribe for securities or other financial instruments. The data contained within this report is based on information derived from reliable sources, but its accuracy or completeness cannot be warranted, expressly or impliedly, by WallStAnalyst.com.